ESEPAPOGENE ZALARNAREPVEC
UNII VA2XPJ9DMK

Substance Identification & Data

This profile provides standardized clinical and technical data for Esepapogene Zalarnarepvec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) VA2XPJ9DMK.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2632271-13-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

VA2XPJ9DMK

CAS Registry Number

2632271-13-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ESEPAPOGENE ZALARNAREPVEC

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C204142

National Cancer Institute reference terminology for clinical and research data.

INN ID

12224

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-173

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Esepapogene Zalarnarepvec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ESEPAPOGENE ZALARNAREPVEC

Common Names & Synonyms

ESEPAPOGENE ZALERNAREPVEC [USAN]

HB-201 COMPONENT R3LCMV-E7E6

RECOMBINANT REPLICATION-COMPETENT ATTENUATED ARENAVIRUS (LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV) STRAIN CLONE 13) EXPRESSING THE GLYCOPROTEIN OF LCMV STRAIN WE INSTEAD OF ITS ENDOGENOUS GLYCOPROTEIN (ALTERNATIVELY DESIGNATED AS RCL13/WE-GP) VECTOR WITH TWO COPIES OF THE SMALL (S) GENOME SEGMENT (S RNA SEGMENT), WITH ONE ENCODING THE VIRAL MEMBRANE GLYCOPROTEIN (GP) AND ONE ENCODING THE VIRAL NUCLEOCAPSID PROTEIN (NP), AND BOTH ENCODING A SYNTHETIC HUMAN PAPILLOMAVIRUS TYPE 16 E7E6 FUSION PROTEIN (WITH MUTATIONS OF C24G, E26G AND C91G IN E7 AND C69G AND C112G IN E6), AND WITH A WILD TYPE LARGE (L) GENOME SEGMENT (L RNA SEGMENT). EXPRESSION OF THE E7E6 FUSION PROTEIN IS UNDER CONTROL OF THE VIRAL EXPRESSION MECHANISM.

RNA (LYMPHOCYTIC CHORIOMENINGITIS VIRUS VECTOR HB-201 SEGMENT L), SUPRAMOLECULAR COMPLEX WITH RNA (LYMPHOCYTIC CHORIOMENINGITIS VIRUS VECTOR HB-201 SEGMENT S-2 HUMAN PAPILLOMAVIRUS 16 (24-GLYCINE,26-GLYCINE,91-GLYCINE) GENE E7 PROTEIN FUSION PROTEIN WITH (69-GLYCINE,112-GLYCINE) GENE E6 PROTEIN TRANSGENE PLUS MEMBRANE GLYCOPROTEIN GPC-SPECIFYING), SUPRAMOLECULAR COMPLEX WITH RNA (LYMPHOCYTIC CHORIOMENINGITIS VIRUS VECTOR HB-201 SEGMENT S-1 HUMAN PAPILLOMAVIRUS 16 (24-GLYCINE,26-GLYCINE,91-GLYCINE) GENE E7 PROTEIN FUSION PROTEIN WITH (69-GLYCINE,112-GLYCINE) GENE E6 PROTEIN TRANSGENE PLUS NUCLEOCAPSID PROTEIN-SPECIFYING)

Technical Codes

HB-201 SEGMENT L

TT1-E7E6 COMPONENT R3LCMV-E7E6

External Clinical & Regulatory Resources

Previous UNIIVA2I6U65DD

Next UNIIVA34QWD2AN